About ANX007 and Phase 2 ARCHER TrialANX007 is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical ...

Light-activated drugs restored vision-related behavior in blind mice, raising hopes for a simpler treatment for damaged ...

Blinding diseases lead to permanent vision loss by damaging photoreceptor cells, which humans cannot naturally regenerate. While researchers are working on new methods to replace or regenerate these ...

Scientists from Tokyo Metropolitan University have identified a new photoreceptor in cyanobacteria with a modification in part of its structure which makes it sensitive to green/teal light. The ...

Please provide your email address to receive an email when new articles are posted on . PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Reenie McCarthy of ...